These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
521 related articles for article (PubMed ID: 35352187)
81. Successful Burosumab Treatment in an Adult Patient with X-Linked Hypophosphatemia and Chronic Kidney Disease Stage 3b. Michon-Colin A; Bouderlique E; Prié D; Maruani G; Nevoux J; Briot K; Courbebaisse M Calcif Tissue Int; 2024 Mar; 114(3):310-314. PubMed ID: 38195892 [TBL] [Abstract][Full Text] [Related]
82. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia]. Michigami T Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640 [TBL] [Abstract][Full Text] [Related]
83. Iron replacement ameliorates hypophosphatemia in autosomal dominant hypophosphatemic rickets: A review of the role of iron. Menon LP; Weinstein RS Bone; 2020 Feb; 131():115137. PubMed ID: 31756522 [TBL] [Abstract][Full Text] [Related]
84. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126 [TBL] [Abstract][Full Text] [Related]
85. Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review. Yavropoulou MP; Kotsa K; Gotzamani Psarrakou A; Papazisi A; Tranga T; Ventis S; Yovos JG Hormones (Athens); 2010; 9(3):274-8. PubMed ID: 20688626 [TBL] [Abstract][Full Text] [Related]
86. Novel Therapeutic Agents for Rare Diseases of Calcium and Phosphate Metabolism. Roumpou A; Yavropoulou MP; Chronopoulos E; Kassi E Horm Metab Res; 2022 Oct; 54(10):645-657. PubMed ID: 36049757 [TBL] [Abstract][Full Text] [Related]
87. X-Linked Hypophosphatemia: A New Era in Management. Dahir K; Roberts MS; Krolczyk S; Simmons JH J Endocr Soc; 2020 Dec; 4(12):bvaa151. PubMed ID: 33204932 [TBL] [Abstract][Full Text] [Related]
88. X-linked hypophosphatemic rickets: an Italian experts' opinion survey. Emma F; Cappa M; Antoniazzi F; Bianchi ML; Chiodini I; Eller Vainicher C; Di Iorgi N; Maghnie M; Cassio A; Balsamo A; Baronio F; de Sanctis L; Tessaris D; Baroncelli GI; Mora S; Brandi ML; Weber G; D'Ausilio A; Lanati EP Ital J Pediatr; 2019 May; 45(1):67. PubMed ID: 31151476 [TBL] [Abstract][Full Text] [Related]
89. Management of X-linked hypophosphatemia in adults. Lecoq AL; Brandi ML; Linglart A; Kamenický P Metabolism; 2020 Feb; 103S():154049. PubMed ID: 31863781 [TBL] [Abstract][Full Text] [Related]
90. [Rare causes of Hypophosphatemia: diagnostic approach]. Trombetti A; Fokstuen S; Parvex P Rev Med Suisse; 2023 Apr; 19(823):770-775. PubMed ID: 37133959 [TBL] [Abstract][Full Text] [Related]
91. Evaluation of bone markers in hypophosphatemic rickets/osteomalacia. Nagata Y; Imanishi Y; Ishii A; Kurajoh M; Motoyama K; Morioka T; Naka H; Mori K; Miki T; Emoto M; Inaba M Endocrine; 2011 Oct; 40(2):315-7. PubMed ID: 21822687 [TBL] [Abstract][Full Text] [Related]
92. Burosumab for Pediatric X-Linked Hypophosphatemia. Imel EA Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403 [TBL] [Abstract][Full Text] [Related]
93. New Developments in the Treatment of X-Linked Hypophosphataemia: Implications for Clinical Management. Saraff V; Nadar R; Högler W Paediatr Drugs; 2020 Apr; 22(2):113-121. PubMed ID: 31965544 [TBL] [Abstract][Full Text] [Related]
94. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. Carpenter TO; Imel EA; Ruppe MD; Weber TJ; Klausner MA; Wooddell MM; Kawakami T; Ito T; Zhang X; Humphrey J; Insogna KL; Peacock M J Clin Invest; 2014 Apr; 124(4):1587-97. PubMed ID: 24569459 [TBL] [Abstract][Full Text] [Related]
95. Global guidance for the recognition, diagnosis, and management of tumor-induced osteomalacia. Jan de Beur SM; Minisola S; Xia WB; Abrahamsen B; Body JJ; Brandi ML; Clifton-Bligh R; Collins M; Florenzano P; Houillier P; Imanishi Y; Imel EA; Khan AA; Zillikens MC; Fukumoto S J Intern Med; 2023 Mar; 293(3):309-328. PubMed ID: 36511653 [TBL] [Abstract][Full Text] [Related]
96. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. Carpenter TO; Insogna KL; Zhang JH; Ellis B; Nieman S; Simpson C; Olear E; Gundberg CM J Clin Endocrinol Metab; 2010 Nov; 95(11):E352-7. PubMed ID: 20685863 [TBL] [Abstract][Full Text] [Related]
97. Dramatic Transformation After Burosumab in a Young Boy With X-linked Hypophosphatemia: A Life-Changing Saga. Baradhi K Cureus; 2022 Feb; 14(2):e22340. PubMed ID: 35371638 [TBL] [Abstract][Full Text] [Related]
98. Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption. Johnson K; Levine K; Sergi J; Chamoun J; Roach R; Vekich J; Favis M; Horn M; Cao X; Miller B; Snyder W; Aivazian D; Reagan W; Berryman E; Colangelo J; Markiewicz V; Bagi CM; Brown TP; Coyle A; Mohammadi M; Magram J J Bone Miner Res; 2017 Oct; 32(10):2062-2073. PubMed ID: 28600887 [TBL] [Abstract][Full Text] [Related]
99. [FGF23 and bone metabolism]. Ito N; Fukumoto S Clin Calcium; 2005 Jul; 15(7):43-8. PubMed ID: 15995295 [TBL] [Abstract][Full Text] [Related]
100. Rickets Types and Treatment with Vitamin D and Analogues. Biasucci G; Donini V; Cannalire G Nutrients; 2024 Jan; 16(3):. PubMed ID: 38337700 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]